Unicycive Therapeutics Highlights Innovations at Kidney Week 2024
Unicycive Therapeutics Showcases Key Research at ASN Kidney Week
LOS ALTOS, Calif. – Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a pioneering biotechnology company focused on developing effective therapies for kidney diseases, has recently made a significant announcement. A poster presentation concerning their innovative treatment Oxylanthanum Carbonate (OLC) was selected for a Late-Breaker session at the American Society of Nephrology (ASN) Kidney Week 2024. Thus, the excitement surrounding OLC continues to build, especially as the company prepares to share more groundbreaking insights into their additional research on both OLC and another candidate, UNI-494.
Details About the Late-Breaking Science Poster
Late Breaking Science Poster:
Title: Effects of Oxylanthanum Carbonate in Patients Receiving Maintenance Hemodialysis with Hyperphosphatemia
Lead Author: Geoffrey A. Block, MD, FASN, Associate Chief Medical Officer & Senior Vice President at U.S. Renal Care.
Session Title: Late-Breaking Science Posters [LB-PO]
Poster Board: #TH-PO1188
Date/Time: Thursday, October 24, 2024, from 10:00 a.m. – 12:00 p.m. PT
Exciting Additional Presentations
Unicycive will also be delivering three additional poster presentations at Kidney Week, showcasing their comprehensive research efforts:
1. Title: Intravenous UNI-494 Slows Progression or Halts/Reverses Acute Kidney Injury
Lead Author: Satya Medicherla, Ph.D., Vice President of Preclinical Pharmacology at Unicycive.
Session Title: AKI: Mechanisms
Poster Board: #FR-PO155
Date/Time: Friday, October 25, 2024, from 10:00 a.m. – 12:00 p.m. PT
Other Notable Poster Presentations
2. Title: Combination Oxylanthanum Carbonate and Tenapanor Lowers Urinary Phosphate Excretion in Rat
Lead Author: Satya Medicherla, Ph.D.
Session Title: CKD-MBD: Basic and Translational
Poster Board: #SA-PO243
Date/Time: Saturday, October 26, 2024, from 10:00 a.m. – 12:00 p.m. PT
Final Presentation
3. Title: UNI-494 Phase I Safety, Tolerability, and Pharmacokinetics
Lead Author: Guru Reddy, PH.D., Vice President of Preclinical R&D at Unicycive.
Session Title: AKI: Clinical, Outcomes, and Trials - Management
Poster Board: #SA-PO036
Date/Time: Saturday, October 26, 2024, from 10:00 a.m. – 12:00 p.m. PT
Understanding Oxylanthanum Carbonate (OLC)
Oxylanthanum carbonate is emerging as a next-generation lanthanum-based phosphate-binding agent, specifically designed for treating hyperphosphatemia in patients suffering from chronic kidney disease (CKD). With over forty patents issued globally, OLC demonstrates potential advantages over existing treatments as it promises to reduce the pill burden for patients, thus likely improving adherence. The results from a survey completed in 2022 indicated that nephrologists are particularly focused on finding solutions that alleviate the pill burden associated with traditional phosphate binders.
A Promising Market Opportunity
The market for addressing hyperphosphatemia is colossal, projected to exceed $2.5 billion with a significant portion attributed to the U.S. This thriving sector continues to emphasize the necessity for effective treatments, as a staggering 75% of dialysis patients in the U.S. do not reach their recommended phosphorus levels, despite the options available.
Regulatory Pathway and Clinical Trials
Unicycive is actively seeking FDA approval for OLC via the 505(b)(2) regulatory pathway. The company has conducted two pivotal clinical studies on healthy volunteers, including a safety and tolerability study, establishing the groundwork for future progress. A key clinical trial also examined the efficacy of OLC in CKD patients on hemodialysis, resulting in favorable outcomes.
About UNI-494
UNI-494 represents an advancement in the treatment of acute kidney injury (AKI). As a novel nicotinamide ester derivative, it uniquely activates mitochondrial potassium channels, spotlighting the importance of mitochondrial function in kidney health. This product is currently undergoing a Phase 1 dose-ranging safety study, with results anticipated soon, further underscoring Unicycive’s commitment to combatting kidney illnesses.
Conclusion
Unicycive Therapeutics continues to make strides in the field of kidney disease therapy, committed to furthering innovation for patients suffering from these conditions. Their upcoming presentations at ASN Kidney Week 2024 signify not only the advancements of OLC and UNI-494 but also the company’s dedication to addressing the serious challenges within nephrology.
Frequently Asked Questions
What is Oxylanthanum Carbonate (OLC)?
OLC is an innovative lanthanum-based phosphate binding agent aimed at treating hyperphosphatemia in chronic kidney disease patients.
When will Unicycive present their research?
Unicycive will present at ASN Kidney Week from October 24-27, 2024.
Who are the lead authors for the presentations?
Lead authors include several prominent professionals, such as Geoffrey A. Block, MD, and Satya Medicherla, Ph.D.
What is the market potential for treating hyperphosphatemia?
The global market for hyperphosphatemia treatments is projected to exceed $2.5 billion with significant unmet needs in patient adherence.
What is the significance of UNI-494?
UNI-494 is potentially a significant advancement in treating acute kidney injury through its unique mechanism of enhancing mitochondrial function.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- DataTrace Enhances Title Services with New Digital Solutions
- Exploring the Transformative Role of Trust in Public Relations
- INVO and NAYA Biosciences Merger Expands Treatment Access
- MACH Alliance Elevates Its Role as a Leader in Technology
- Virtual Annual Meeting Set for Reading International Shareholders
- AGCO Plans Third-Quarter 2024 Earnings Call for Investors
- BIO-key Innovates Authentication Solutions at ISC² Security Forum
- Longeveron Presents Groundbreaking Alzheimer's Data at CTAD24
- Exciting Leadership Addition at Sify Technologies Limited
- Society6 Elevates User Experience with Stunning Website Makeover
Recent Articles
- MyOme Partners with Broad Labs for Genetics Initiative
- Schouw & Co. Reports Progress on Share Buy-Back Initiative
- Unicycive Therapeutics Advances Kidney Treatments at ASN 2024
- RYVYL Inc. to Showcase Innovations at LD Micro Event
- Permira Successfully Completes Tender Offer for Squarespace
- SurplusGLOBAL Enhances Semiconductor Distribution with AI
- Kraig Labs Advances Production of Revolutionary Spider Silk
- Codexis Welcomes New Employees with Equity Grants and Awards
- Nykredit Realkredit A/S Publishes Important Prepayment Data
- Totalkredit A/S Updates on Prepayment Data and Insights
- Codexis Expands Team with New Employment Inducement Grants
- New Insights on Pidnarulex from Senhwa Biosciences' Study
- Moshe Bajnon to Steer Nuveen Private Capital's Wealth Strategy
- Dot Ai and ShoulderUp Technology Merge Ahead of Nasdaq Listing
- Poll Indicates Trump Leading Among Catholic Voters in 2024
- Market Outlook: Focus on Q3 Earnings and Economic Indicators
- Discover Butterball's Easy Cook From Frozen Turkey Option
- Longboard Pharmaceuticals Shares Surge Following Major Acquisition
- Explore Risks in Film with New Documentary 'Safe Sets'
- Gogo Business Aviation Anticipates Surge in Galileo HDX Demand
- BELFOR Franchise Group Brands Shine in Top 400 Recognition
- Rural Healthcare Transformation: Data-Driven Innovations in Practice
- Top Tips from HVAC Experts for a Cozy Winter Experience
- Alpine Income Property Trust: Recent Performance and Insights
- BD and Hamilton Revolutionize Genomic Research Automation
- Denali Therapeutics: Navigating Challenges and Future Innovations
- Mirikizumab's Groundbreaking Results in Crohn’s Disease Treatment
- Goldman Sachs Boosts Ibotta to Buy: A Strategic Move
- NCR Voyix Retains Buy Rating with $20 Price Target Amid Growth
- Impact of EU Tariffs on BYD's Electric Vehicle Strategy
- Tragic Tesla Accident in France Claims Four Lives
- Politecnico di Torino Enhances Its Impact on Space Research
- Soil Compaction Machines Market Projects Steady Growth Ahead
- KOALA AI: A Game-Changer in Cryptocurrency Listings and Community
- Ferrari N.V. Announces Significant Share Buyback Progress
- Auddia Achieves Impressive User Retention While Focusing on Growth
- FHLB Dallas and Austin Bank Supporting Native American Housing
- SANY Group's Lighthouse Factory Recognized for Sustainable Excellence
- Understanding Market Operations on Columbus Day for Investors
- Surging Growth Forecast for the Plastic Hot and Cold Pipe Market
- Global Markets React to Economic Shifts and Demand Fluctuations
- Aluminium Supply Challenges Spark Price Predictions Through 2026
- Eli Lilly's Mirikizumab Shows Promising Outcomes for Crohn's Disease
- Domino's Pizza Sees Share Buyback as Positive amid Sales Pressure
- GE Aerospace: Prospects Boosted by Boeing Strike and Market Dynamics
- BD Unveils Advanced Robotics for Streamlined Research Automation
- Turnstone Biologics Faces Downgrade Amid Strategic Shift
- Arch Resources and CONSOL Energy Merge, Securing HSR Approval
- Lundbeck's Strategic Bid to Acquire Longboard Pharmaceuticals
- ProLogium's Innovative 100% Silicon Anode Revolutionizes EVs